Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 3.99B 3.68B 3.43B 6.46B 433B 6.59B 44.23B 17.14B 212B 17.08B 16.71B 739B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.13B 3.8B 3.54B 6.67B 447B 6.81B 45.67B 17.7B 219B 17.64B 17.26B 763B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
3 months+0.35%
6 months+1.76%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 5.88
Extreme 5.88
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap.
04-27Issuer sale

Director

301,815 0.0961%
04-27Issuer sale

Executive/Senior Manager

1,100,626 0.3505%
04-27Issuer sale

Chairman

419,487 0.1336%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+148.12%+15.37% 4.55B
-0.32%+4.69%+0.64%+6.23% 48.62B
+0.12%+10.45%+408.29%+600.97% 39.86B
+5.17%+9.47%+24.96%-9.60% 33.91B
+2.02%+4.91%+18.59%+63.06% 32.32B
+0.69%+1.04%+14.23%+30.86% 24.73B
+0.40%+12.51% - - 16.63B
+2.64%+6.00%+69.30%+126.33% 15.52B
+0.44%+0.73%+13.39%+18.10% 13.63B
+0.77%+10.67%+17.58%-30.04% 13.41B
Average +1.22%+6.36%+79.46%+91.25% 24.32B
Weighted average by Cap. +1.29%+7.01%+89.49%+126.28%

Financials

2024 2025
Net sales 528M 464M 427M 398M 750M 50.23B 766M 5.14B 1.99B 24.65B 1.98B 1.94B 85.8B 634M 557M 513M 478M 901M 60.3B 919M 6.16B 2.39B 29.6B 2.38B 2.33B 103B
Net income -56.11M -49.26M -45.34M -42.25M -79.68M -5.33B -81.3M -545M -211M -2.62B -211M -206M -9.11B -27.11M -23.8M -21.91M -20.42M -38.5M -2.58B -39.29M -264M -102M -1.27B -102M -99.59M -4.4B
Net Debt 194M 170M 157M 146M 275M 18.42B 281M 1.88B 729M 9.04B 727M 712M 31.46B 149M 131M 120M 112M 211M 14.15B 216M 1.45B 560M 6.95B 559M 547M 24.17B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock